What this covers
Nael and Matt work through AMETEK, a maker of mission-critical components whose revenue has compounded at roughly 7% to 9% a year since 1955, across several leadership teams. The discussion is organized around what Fakhry calls the AMETEK Growth Model. They trace it to Walter Blankley, an engineer who became CEO in 1990, cut the dividend by two-thirds and bought back a third of the shares. His successors, Frank Hermance and David Zapico, were also engineers who spent decades inside the company.
The middle of the episode covers why the business is durable. Its end markets are regulated, so its parts are specified into customer designs. They are also a tiny share of the cost of a jet or a submarine, which supports pricing power. Through-cycle organic growth is about 4%, roughly 3 points of it price, and pricing 50 to 100 basis points ahead of inflation feeds margin expansion. The downturn figures for 2001, 2009, 2015-16 and COVID show revenue falling much further than EBITDA. The claim that quality cyclicals rebound within a year or two is flagged as contested.
The later stretch turns to capital allocation. About 75% of free cash flow over the past decade went to acquisitions, with no equity issued and a flat share count for about 20 years. Roughly half of deals originate with business unit managers, whose pay is largely tied to their own unit's results. Past errors, such as buying Ketema and Reading Alloys, came from favoring cash over growth. The sharpest debate concerns the $1.9B Paragon Medical deal at 12x to 13x, against a historical 8x to 10x, and whether rising returns on capital justify paying up.
Fakhry argues AMETEK's two-decade compounding comes from a repeatable model of dominating small niche markets, pushing decisions down to business units, and funding serial acquisitions with free cash flow, and that the main risk is whether that model can absorb larger deals.
- AMETEK targets niche markets of about $200M to $300M where it holds 25% to 30% share and typically ranks #1 or #2, avoiding markets of $1B or more where larger players compete
- Organic growth of about 4% through the cycle plus about 4% from acquisitions produces roughly 8% revenue growth, in line with the 7% to 9% historical rate
- The Paragon Medical deal at $1.9B for roughly $150M EBITDA (12x to 13x) is larger than historical deals and is the largest risk Fakhry identifies
Divesting and selling businesses matters as much as acquiring them in capital allocation.
- Over the past decade about 75% of AMETEK's free cash flow went to acquisitions, with the remaining 25% split between dividends and buybacks.
“75% of free cash flow over the past decade has gone to acquisitions”
- AMETEK's willingness to spin off or sell slow-growth businesses, such as the Ketema units in 1988 and Reading Alloys in 2020, is as important to capital allocation as its acquisitions.
“When they had those really slow growth business units, they spun them off because they said, 'It's not core to the business.'”
- Matt argues that great capital allocators are judged as much by sales as by purchases, and that portfolio-level thinking about divestitures is rare among management teams.
“it's equally important to make great sales.”
Running diversified niche businesses as a portfolio strains unit-level incentives.
- Matt suggests that bundling businesses can cannibalize individual units and depress unit-level results, creating a tension between portfolio-level optimization and business-unit incentives.
“have you come across any downsides to the operating model like that or challenges that they've had to work through?”
- Matt argues the usual pattern of conglomerates is to spin out and focus on single product lines, so AMETEK's willingness to keep and manage a diversified set of niche businesses is unusual.
“the conglomerates or the mixed end markets tend to end up spinning out and almost becoming just more focused on a single product line.”
A 15x to 20x earnings multiple is fair given high cash conversion and strong returns.
- Matt argues a 15x to 20x earnings multiple, with premium to market for a business converting earnings to cash above 100% and generating strong returns on capital, is a completely fair valuation.
“let's say, 15 to 20x for a business that converts earnings with the cash flow above 100% and has those returns on capital, I think getting some premium to that is certainly not unreasonable”
Peripheral context: international revenue share and a related companion episode.
- A companion Colossus episode featured Danaher co-founder Mitch Rales in his first long-form interview.
“Danaher Co-Founder, Mitch Rales. This is Mitch's first recorded long-form interview of any kind”
- Roughly half of AMETEK's sales come from outside the United States, which Matt noted as a notable feature of the revenue base.
“50% is coming from outside of the U.S.”